Pt no. |
Age at Diagnosis* |
Sex |
Ethnicity |
Attack Frequency |
Current Treatment Regimen |
MGUS |
1 |
45 |
M |
C |
Every 4-6 weeks |
IVIG |
IgG kappa |
2 |
49 |
F |
C |
Weekly/monthly |
IVIG |
IgG kappa |
3 |
45 |
M |
C |
Every weekend |
Infliximab |
IgG kappa |
4 |
55 |
M |
C |
> 2/yr |
IVIG |
IgG kappa |
5 |
46 |
F |
C |
5-10 day intervals |
N/A (deceased) |
IgG lambda |
6 |
42 |
M |
C |
3-4 year intervals |
Theophylline |
IgG kappa |
7 |
32 |
M |
C |
3-5 year intervals |
IVIG |
IgG kappa |
8 |
59 |
M |
C |
Single episode |
None |
IgG kappa |
9 |
65 |
M |
C |
3-4/year |
IVIG |
IgG kappa |
10 |
39 |
F |
C |
Chronic |
T/T** |
ND# |
11 |
48 |
F |
C |
Infrequent |
T/T |
IgG lambda |
12 |
48 |
M |
C |
weekly |
IVIG |
IgG kappa |
13 |
50 |
F |
C |
> 2x/yr |
IVIG |
IgG kappa |
14 |
51 |
M |
C |
> 2x/yr |
IVIG |
IgG |
15 |
53 |
M |
C |
Weekly |
IVIG |
IgG lambda |
16 |
40 |
F |
C |
Chronic |
Theophylline |
IgG kappa |
17 |
43 |
F |
C |
3-4 year interval |
None |
IgG kappa |
18 |
64 |
F |
C |
Chronic |
Theophylline |
IgG kappa |
19 |
48 |
M |
AA |
3-4/yr |
IVIG |
IgG lambda |
20 |
43 |
M |
C |
Bimonthly |
IVIG |
IgG kappa |
21 |
65 |
M |
C |
Single episode |
Theophylline |
IgG kappa |
22 |
43 |
M |
C |
< 2x/yr |
IVIG |
IgG kappa |
23 |
36 |
F |
C |
< 2x/yr |
IVIG |
IgG kappa |
24 |
66 |
M |
C |
< 2x/yr |
IVIG |
IgG lambda |
25 |
40 |
F |
C |
Single episode |
IVIG |
IgG kappa |
26 |
62 |
M |
C |
< 2x/yr |
IVIG |
IgG kappa |
27 |
7 |
F |
C |
Chronic plus acute |
Subcutaneous IG |
ND# |
28 |
48 |
M |
C |
< 2x/yr |
IVIG |
IgG lambda |
29 |
61 |
M |
C |
3-4 year intervals |
IVIG |
IgG kappa |
30 |
43 |
F |
C |
< 2x/yr |
IVIG |
IgG lambda |
31 |
58 |
F |
C |
Chronic plus acute |
None |
IgM kappa |
32 |
33 |
M |
C |
< 2x/yr |
IVIG |
ND# |
33 |
37 |
F |
C |
Chronic plus acute |
IVIG |
ND# |
34 |
22 mo. |
F |
C |
Every 5-6 months |
|
ND# |
35 |
8 |
C |
C |
Weekly |
IVIG |
ND# |
*Note: Many patients experienced episodes consistent with SCLS prior to formal diagnosis; **: Theophylline plus terbutaline; #: Not detected |
|